Entyvio (vedolizumab) Letter of Medical Necessity
Entyvio (vedolizumab) prior authorization typically requires step therapy through a TNF inhibitor and documentation of moderate-to-severe disease activity. The VARSITY trial data can support first-line use in ulcerative colitis.
FDA-Approved Indications
- ● ulcerative colitis
- ● Crohn's disease
Why Entyvio Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. TNF inhibitor not tried first (step therapy)
- 2. Disease activity scoring not documented (partial Mayo, HBI, SES-CD)
- 3. IV vs subcutaneous formulation not justified
- 4. Induction vs maintenance not specified
What to Include in a Entyvio Letter of Medical Necessity
Document IBD diagnosis with endoscopic confirmation, disease activity scores (partial Mayo for UC, HBI or CDAI and SES-CD for CD), prior conventional and biologic therapies with outcomes, and the clinical rationale for gut-selective integrin blockade — particularly in patients with infection risk or prior systemic immunosuppression concerns.
Key clinical evidence to cite:
- ✓ GEMINI 1 (UC), GEMINI 2 and 3 (CD)
- ✓ VISIBLE 1 and 2 (subcutaneous)
- ✓ VARSITY head-to-head vs adalimumab in UC
Relevant guidelines:
- 📖 AGA 2020 IBD Guidelines
- 📖 ACG 2024 Ulcerative Colitis Guidelines
- 📖 ECCO 2023 Guidelines
Payers Covering Entyvio
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Entyvio Prior Authorization FAQ
Why was my Entyvio prior authorization denied?
The most common denial reasons for Entyvio are: TNF inhibitor not tried first (step therapy); Disease activity scoring not documented (partial Mayo, HBI, SES-CD); IV vs subcutaneous formulation not justified; Induction vs maintenance not specified.
What should a Entyvio Letter of Medical Necessity include?
Document IBD diagnosis with endoscopic confirmation, disease activity scores (partial Mayo for UC, HBI or CDAI and SES-CD for CD), prior conventional and biologic therapies with outcomes, and the clinical rationale for gut-selective integrin blockade — particularly in patients with infection risk or prior systemic immunosuppression concerns.
Which payers cover Entyvio?
Entyvio is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.